Top

Current Atherosclerosis Reports

Published in:

01-07-2021 | Dyslipidemia | Genetics and Genomics (A. Marian, Section Editor)

Apolipoprotein E and Atherosclerosis

Author: A. D. Marais

Published in: Current Atherosclerosis Reports | Issue 7/2021

Abstract

Purpose of Review

The functions, genetic variations and impact of apolipoprotein E on lipoprotein metabolism in general are placed in the context of clinical practice dealing with moderate dyslipidaemia as well as dysbetalipoproteinemia, a highly atherogenic disorder and lipoprotein glomerulopathy.

Recent Findings

Additional variants of apolipoprotein E and participation of apolipoprotein E in inflammation are of interest. The mostly favourable effects of apolipoprotein E2 as well as the atherogenic nature of apolipoproteinE4, which has an association with cognitive impairment, are confirmed. The contribution of remnant lipoproteins of triglyceride-rich lipoproteins, of which dysbetalipoproteinemia represents an extreme, is explored in atherosclerosis. Mimetic peptides may present new therapeutic approaches.

Summary

Apolipoprotein E is an important determinant of the lipid profile and cardiovascular health in the population at large and can precipitate dysbetalipoproteinemia and glomerulopathy. Awareness of apolipoprotein E polymorphisms should improve medical care.

1.••

Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. J Mol Med. 2016;94:739–46. https://doi.org/10.1007/s00109-016-1427-yAn excellent historical and scientific account.CrossRefPubMed

2.••

Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51((2):165–76. https://doi.org/10.1016/j.pathol.2018.11.002Review of apoE variants on dyslipidemia.CrossRefPubMed

3.•

Sniderman AD, Type III. Hyperlipoproteinemia: the forgotten, disregarded, neglected, overlooked, ignored but highly atherogenic, and highly treatable dyslipoproteinemia. Clin Chem. 2019;65(2):225–7. https://doi.org/10.1373/clinchem.2018.298026An important reminder of dysbetalipoproteinemia.CrossRefPubMed

Bennett BJ, Davis RC, Civelek M, Orozco L, Wu J, Qi H, et al. Genetic architecture of atherosclerosis in mice: a systems genetics analysis of common inbred strains. PLoS Genet. 2015;11(12):e1005711. https://doi.org/10.1371/journal.pgen.1005711.CrossRefPubMedPubMedCentral

Getz GS, Reardon CA. ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis. J Lipid Res. 2016;57:758–66. https://doi.org/10.1194/jlr.R067249.CrossRefPubMedPubMedCentral

Huang L, Hua Z, Xiao H, Cheng Y, Xu K, Gao Q, et al. CRISPR/Cas9-mediated apoE-/- and LDLR-/- double gene knockout in pigs elevates serum LDL-C and TC levels. Oncotarget. 2017;8(23):37751–60. https://doi.org/10.18632/oncotarget.17154.CrossRefPubMedPubMedCentral

Shim J, Poulsen CB, Hagensen MK, Larsen T, Heegaard PMH, Christoffersen C, et al. Apolipoprotein E deficiency increases remnant lipoproteins and accelerates progressive atherosclerosis, but not xanthoma formation, in gene-modified minipigs. JACC Basic Transl Sci. 2017;2(5):591–600. https://doi.org/10.1016/j.jacbts.2017.06.004.CrossRefPubMedPubMedCentral

8.•

Wagner T, Bartelt A, Schlein C, Heeren J. Genetic dissection of tissue-specific apolipoprotein E function for hypercholesterolemia and diet-induced obesity. PLoS One. 2015:1–14. https://doi.org/10.1371/journal.pone.0145102A demonstration of the importance of apoE in the liver.

9.••

Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E—a multifunctional protein with implications in various pathologies as a result of its structural features. Comput Struct Biotechnol J. 2017;1:359–65. https://doi.org/10.1016/j.csbj.2017.05.003.CrossRef

10.

Benevides LD, de Carvalho DS, Andrade RFS, Bomfim GC, de Campos Fernandes FM. Evolutionary analysis of apolipoprotein E by Maximum Likelihood and complex network methods. Genet Mol Biol. 2016;39(4):665–73. https://doi.org/10.1590/1678-4685-GMB-2015-016.CrossRefPubMedPubMedCentral

11.

Takacs CN, Andreo U, Belote RL, Pulupa J, Scull MA, Gleason CE, et al. GFP-tagged apolipoprotein E: a useful marker for the study of hepatic lipoprotein egress. Traffic. 2017;18(3):192–204. https://doi.org/10.1111/tra.12467.CrossRefPubMedPubMedCentral

12.•

Chetty PS. Leland Mayneb, Lund-Katz S, Englander SW, Phillip MC. Helical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry. Proc Natl Acad Sci U S A. 2017;114(5):968–73. https://doi.org/10.1073/pnas.1617523114Full description of apoE self-association and formation of HDL.CrossRefPubMedPubMedCentral

13.

Hubin E, Verghese PB, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019;593:1144–53. https://doi.org/10.1002/1873-3468.CrossRefPubMedPubMedCentral

14.••

Lanfranco MF, Ng CA, Rebeck GW. ApoE lipidation as a therapeutic target in Alzheimer’s disease. Int J Mol Sci. 2020;21:6336. https://doi.org/10.3390/ijms21176336Informative about apoE in lipid homoestasis in neurons.CrossRefPubMedCentral

15.

Melhem H, Kallol S, Huang X, Lüthi M, Ontsouka CE, Keogh A, et al. Placental secretion of apolipoprotein A1 and E: the antiatherogenic impact of the placenta. Sci Rep. 2019;9:6225. https://doi.org/10.1038/s41598-019-42522.CrossRefPubMedPubMedCentral

16.

Norda S, Rausch TK, Orlikowsky T, Hütten M, Schulz S, Göpel W, et al. Apolipoprotein E genotype in very preterm neonates with intrauterine growth restriction: an analysis of the german neonatal network cohort. Biomed Res Int. 2017;2017:2837027, 8 pages. https://doi.org/10.1155/2017/2837027.CrossRefPubMedPubMedCentral

17.

Mak ACY, Pullinger CR, Tang LF, Wong JS, Deo RC, Schwarz J-M, et al. Effects of the absence of apolipoprotein E on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 2014;71(10):1228–36. https://doi.org/10.1001/jamaneurol.2014.2011.CrossRefPubMedPubMedCentral

18.•

Pirim D, Radwan ZH, Wang X, Niemsiri V, Hokanson JE, Hamman RF, et al. Apolipoprotein E-C1-C4-C2 gene cluster region and inter-individual variation in plasma lipoprotein levels: a comprehensive genetic association study in two ethnic groups. PLoS One. 14(3):e0214060. https://doi.org/10.1371/journal.pone.0214060The description of common variants affecting apoE.

19.

Low-Kam C, Rhainds D, Lo KS, Barhdadi A, Boul M, Alem S, et al. Variants at the APOE/C1/C2/C4 locus modulate cholesterol efflux capacity independently of high-density lipoprotein cholesterol. J Am Heart Assoc. 2018;7:e009545. https://doi.org/10.1161/JAHA.118.009545.CrossRefPubMedPubMedCentral

20.

Theendakara V, Peters-Libeu CA, Spilman P, Poksay KS, Bredesen DE, Rao RV. Direct transcriptional effects of apolipoprotein E. J Neurosci. 2016;36(3):685–700. https://doi.org/10.1523/JNEUROSCI.3562-15.2016.CrossRefPubMedPubMedCentral

21.•

Babenko VN, Afonnikov DA, Ignatieva EV, Klimov AV, Gusev FE, Rogaev EI. Haplotype analysis of APOE intragenic SNPs. BMC Neurosci. 2018;19(Suppl 1):16. https://doi.org/10.1186/s12868-018-0413-4A very detailed description of variation apoE gene in populations.CrossRefPubMedPubMedCentral

22.

Trusca VG, Fuior EV, Kardassis D, Simionescu M, Gafencu AV. The opposite effect of c-Jun transcription factor on apolipoprotein E gene regulation in hepatocytes and macrophages. Int J Mol Sci. 2019;20:1471. https://doi.org/10.3390/ijms20061471.CrossRefPubMedCentral

23.

Benson MD, Yang Q, Ngo D, Zhu Y, Shen D, Farrell LA, et al. The genetic architecture of the cardiovascular risk proteome. Circulation. 2018;137(11):1158–72. https://doi.org/10.1161/CIRCULATIONAHA.117.029536.CrossRefPubMed

24.

Mancera-Páez O, Estrada-Orozco K, Mahecha MF, Cruz F, Bonilla-Vargas K, Sandoval N, et al. Differential methylation in APOE (Chr19; Exon Four; from 44,909,188 to 44,909,373/hg38) and increased apolipoprotein E plasma levels in subjects with mild cognitive impairment. Int J Mol Sci. 2019;20(6):1394. Published online 2019 Mar 20. https://doi.org/10.3390/ijms20061394.CrossRefPubMedCentral

25.

Ma Y, Smith CE, Lai C-Q, Irvin MR, Parnell LD, Lee Y-C, et al. Genetic variants modify the effect of age on APOE methylation in the Genetics of Lipid Lowering Drugs and Diet Network study. Aging Cell. 2015;14:49–59. https://doi.org/10.1111/acel.12293.CrossRefPubMed

26.

Karlsson IK, Ploner A, Wang Y, Gatz M, Pedersen NL, Hägg S. Apolipoprotein E DNA methylation and late-life disease. Int J Epidemiol. 2018;47:899–907. https://doi.org/10.1093/ije/dyy025.CrossRefPubMedPubMedCentral

27.

Mur J, McCartney DL, Walker RM, Campbell A, Bermingham ML, Morris SW, et al. DNA methylation in APOE: the relationship with Alzheimer’s and with cardiovascular health. Alzheimers Dement. 2020;6:e12026. https://doi.org/10.1002/trc2.12026.CrossRef

28.•

Rebeck GW. The role of APOE on lipid homeostasis and inflammation in normal brains. J Lipid Res. 2017;58:1493–9. https://doi.org/10.1194/jlr.R075408Multiple aspects of lipid metabolism and apoE including post-translational modification. Broadly informative of apoE and particularly on inflammation and discusses lower levels of apoE4.CrossRefPubMedPubMedCentral

29.••

Getz GS, Reardon CA. Apoproteins E, A-I, and SAA in Macrophage pathobiology related to atherogenesis. Front Pharmacol. 2019;10:536. https://doi.org/10.3389/fphar.2019.00536An in-depth review of inflammation relevant to apoE and macrophages.CrossRefPubMedPubMedCentral

30.

Centa M, Prokopec KE, Garimella MG, Habir K, Hofste L, Stark JM, et al. Acute loss of apolipoprotein E triggers an autoimmune response that accelerates atherosclerosis. Arterioscler Thromb Vasc Biol. 2018;38(8):e145–58. https://doi.org/10.1161/ATVBAHA.118.310802.CrossRefPubMedPubMedCentral

31.

Giordano-Mooga S, Datta G, Wolkowicz P, Garber DW, Palgunachari M, White CR, et al. Apolipoprotein E mimetic peptide AEM-2 attenuates mitochondrial injury and apoptosis in human THP-1 macrophages. Curr Top Pept Protein Res. 2018;19:15–25.PubMedPubMedCentral

32.

Yin C, Ackermann S, Ma Z, Mohanta SK, Zhang C, Li Y, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019;25(3):496–506. https://doi.org/10.1038/s41591-018-0336-8.CrossRefPubMedPubMedCentral

33.

Nissilä E, Hakala P, Leskinen K, Roig A, Syed S, Van Kessel KPM, et al. Complement factor H and apolipoprotein E participate in regulation of inflammation in THP-1 macrophages. Front Immunol. 2018;9:2701. https://doi.org/10.3389/fimmu.2018.02701.CrossRefPubMedPubMedCentral

34.••

Bouchareychas L, Raffai RL. apolipoprotein E and atherosclerosis: from lipoprotein metabolism to microRNA control of inflammation. J Cardiovasc Dev Dis. 2018;5:30. https://doi.org/10.3390/jcdd5020030A useful review including pleiotropic effects of apoE.CrossRefPubMedCentral

35.

Teter B, Ladu MJ, Sullivan PM, Frautschy SA, Cole GM. Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. Neuroreport. 2016;27(11):791–5. https://doi.org/10.1097/WNR.0000000000000608.CrossRefPubMedPubMedCentral

36.

Zhong H, Cai Y, Cheng J, Cai D, Chen L, Su C, et al. Apolipoprotein E epsilon 4 enhances the association between the rs2910164 polymorphism of miR-146a and risk of atherosclerotic cerebral infarction. J Atheroscler Thromb. 2016;23:819–29. https://doi.org/10.5551/jat.32904.CrossRefPubMedPubMedCentral

37.

Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci. 2019;9:19. https://doi.org/10.1186/s13578-019-0282-2.CrossRefPubMedPubMedCentral

38.

Peng KY, Perez-Gonzalez R, Alldred MJ, Goulbourne CN, Morales-Corraliza J, Saito M, et al. Apolipoprotein E4 genotype compromises brain exosome production. Brain. 2019;142:163–75. https://doi.org/10.1093/brain/awy289.CrossRefPubMed

39.

Sack FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26(1):56–63. https://doi.org/10.1097/MOL.0000000000000146.CrossRef

40.

Ramms B, Gordts PLSM. Apolipoprotein C-III in triglyceriderich lipoprotein metabolism. Curr Opin Lipidol. 2018;29:171–9. https://doi.org/10.1097/MOL.0000000000000502.CrossRefPubMed

41.

TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31. https://doi.org/10.1056/NEJMoa1307095.CrossRef

42.

Jepsen AM, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG. Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease. Clin Chem. 2016;62(4):593–604. https://doi.org/10.1373/clinchem.2015.253757.CrossRefPubMed

43.

Lawler PR, Akinkuolie AO, Chu AY, Shah SH, Kraus WE, Craig D, et al. Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol. J Am Heart Assoc. 2017;6(7):e005549. https://doi.org/10.1161/JAHA.117.005549.CrossRefPubMedPubMedCentral

44.••

Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri M. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta. 2019;490:1–5. https://doi.org/10.1016/j.cca.2018.12.014A comprehensive review.CrossRefPubMed

45.•

Lane-Donovan C, Herz J. ApoE, ApoE receptors, and the synapse in Alzheimer’s disease. Trends Endocrinol Metab. 2017;28(4):273–84. https://doi.org/10.1016/j.tem.2016.12.001Complexities of apoE metabolism in the nervous will also indicate potential effects elsewhere.CrossRefPubMedPubMedCentral

46.

Fischer AW, Albers K, Krott LM, Hoffzimmer B, Heine M, Schmale H, et al. The adaptor protein PID1 regulates receptor dependent endocytosis of postprandial triglyceride-rich lipoproteins. Mol Metab. 2018;16:88e99. https://doi.org/10.1016/j.molmet.2018.07.010.CrossRef

47.

Anower-E-Khuda F, Singh G, Deng Y, Gordts PLSM, Esko JD. Triglyceride-rich lipoprotein binding and uptake by heparan sulfate proteoglycan receptors in a CRISPR/Cas9 library of Hep3B mutants. Glycobiology. 2019;29(8):582–92. https://doi.org/10.1093/glycob/cwz037.CrossRefPubMedPubMedCentral

48.

Love-Gregory L, Kraja AT, Allum F, Aslibekyan S, Hedman AK, Duan Y, et al. Higher chylomicron remnants and LDL particle numbers associate with CD36 SNPs and DNA methylation sites that reduce CD36. J Lipid Res. 2016;57:2176–84. https://doi.org/10.1194/jlr.P065250.CrossRefPubMedPubMedCentral

49.

Plochberger B, Sych T, Weber F, Novacek J, Axmann M, Stangl H, et al. Lipoprotein particles interact with membranes and transfer their cargo without receptors. Biochemistry. 2020;59:4421–8. https://doi.org/10.1021/acs.biochem.0c00748.CrossRefPubMed

50.

Heeren J, Beisiegel U, Grewal T. Apolipoprotein E recycling: Implications for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:442–8. https://doi.org/10.1161/01.ATV.0000201282.64751.47.CrossRefPubMed

51.

Yang H, Zhang N, Okoro EU, Guo Z. Transport of apolipoprotein B-containing lipoproteins through endothelial cells is associated with apolipoprotein E-carrying HDL-like particle formation. Int J Mol Sci. 2018;19:3593. https://doi.org/10.3390/ijms19113593.CrossRefPubMedCentral

52.••

Balling M, Langsted A, Afzal S, Varbo A, Smith GD, Nordestgaard BG. A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals. Atherosclerosis. 2019;286:97–104. https://doi.org/10.1016/j.atherosclerosis.2019.05.011A very complete analysis of lipids and lipoproteins in a large cohort.CrossRefPubMed

53.

Remaley AT, Otvos JD. Methodological issues regarding: “A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals”. Atherosclerosis. 2020. https://doi.org/10.1016/j.atherosclerosis.2020.01.020.

54.

Chen J, Kuang J, Tang X, Mao L, Guo X, Luo Q, et al. Comparison of calculated remnant lipoprotein cholesterol levels with levels directly measured by nuclear magnetic resonance. Lipids Health Dis. 2020;132:1–13. https://doi.org/10.1186/s12944-020-01311-w.CrossRef

55.

Hirao Y, Nakajima K, Machida T, Murakami M, Ito Y. Development of a novel homogenous assay for remnant lipoprotein particle cholesterol. J Appl Lab Med. 2018;3(1):26–36. https://doi.org/10.1373/jalm.2017.024919.CrossRefPubMed

56.

Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, et al. Remnant-like particle cholesterol, low-density lipoprotein triglycerides and incident cardiovascular disease. J Am Coll Cardiol. 2018;72(2):156–69. https://doi.org/10.1016/j.jacc.2018.04.050.CrossRefPubMedPubMedCentral

57.

Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24:95–109. https://doi.org/10.5551/jat.RV16003.CrossRefPubMedPubMedCentral

58.

Bagdade JD, Jilma B, Hudgins LC, Alaupovic P, McCurdy CE. LpA-II:B:C:D:E: a new immunochemically defined acute phase lipoprotein in humans. Lipids Health Dis. 2018;17:127. https://doi.org/10.1186/s12944-018-0769-6.CrossRefPubMedPubMedCentral

59.••

Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: much more than lipid transporters. Int J Mol Sci. 2020;21:732. https://doi.org/10.3390/ijms21030732An up-to-date review.CrossRefPubMedCentral

60.

Kajani S, Curley S, McGillicuddy FC. Unravelling HDL—looking beyond the cholesterol surface to the quality within Int. J Mol Sci. 2018;19:1971. https://doi.org/10.3390/ijms190719711-23.CrossRef

61.

Singh SA, Andraski AB, Pieper B, Goh W, Mendivil CO, Sacks FM, et al. Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring. J Lipid Res. 2016;57:714–28. https://doi.org/10.1194/jlr.D061432.CrossRefPubMedPubMedCentral

62.

Trieb M, Horvath A, Birner-Gruenberger R, Spindelboeck W, Stadlbauer V, Taschler U, et al. Liver disease alters high-density lipoprotein composition, metabolism and function. Biochim Biophys Acta. 2016;1861(7):630–8. https://doi.org/10.1016/j.bbalip.CrossRefPubMedPubMedCentral

63.

Rosales C, Tang D, Gillard BK, Courtney HS, Pownall HJ. Apolipoprotein E mediates enhanced plasma HDL cholesterol clearance by low dose streptococcal serum opacity factor via hepatic LDL receptors in vivo. Arterioscler Thromb Vasc Biol. 2011;31(8):1834–41. https://doi.org/10.1161/ATVBAHA.111.224360.CrossRefPubMedPubMedCentral

64.

Moriarty PM, Varvel SA, Gords PLSM, McConnell JP, Tsimikas S. Lp(a) mass levels increase significantly according to APOE genotype: an analysis of 431,239 patients. Arterioscler Thromb Vasc Biol. 2017;37(3):580–8. https://doi.org/10.1161/ATVBAHA.116.308704.CrossRefPubMedPubMedCentral

65.

Blanchard V, Croyal M, Khantalin I, Ramin-Mangata S, Chemello K, Nativel B, et al. Reduced lipoprotein(a) associated with the apolipoprotein E2 genotype confers cardiovascular protection in familial hypercholesterolemia. JACC Basic Transl Sci. 2019;4(3):425–7.CrossRefPubMedPubMedCentral

66.

Hopkins PN, Brinton EA, Nanjee MN. Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep. 2014;6:440. 1-12. https://doi.org/10.1007/s11883-014-0440-2.CrossRef

67.

Hazard WR, Porte D, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type III hyperlipoproteinemia). Metabolism. 1972;21(11):1009–19. https://doi.org/10.1016/0026-0495(72)90031-5.CrossRef

68.

Blum CB. Type III hyperlipoproteinemia: still worth considering? Prog Cardiovasc Dis. 2016;59:119–24. https://doi.org/10.1016/j.pcad.2016.07.007.CrossRefPubMed

69.

Salinas CAA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol. 2020;31:132–9. https://doi.org/10.1097/MOL.0000000000000682.CrossRefPubMed

70.

Le R, Abbas M, McIntyre AD, Hegele RA. Severe combined dyslipidemia with a complex genetic basis. J Investig Med High Impact Case Rep. 2019;7:1–5. https://doi.org/10.1177/2324709619877050.CrossRef

71.••

Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P. The spectrum of type III hyperlipoproteinemia. J Clin Lipidol. 2018;12:1383–9 Dysbetalipoproteinemia review and guides that apoB can discriminate dysbetalipoproteinemia.CrossRefPubMed

72.•

Boot CS, Middling E, Allen J, Neely RDG. Evaluation of non-HDL cholesterol to apolipoprotein B ratio as a screening test for dysbetalipoproteinemia. Clin Chem. 2019;65:313–20. https://doi.org/10.1373/clinchem.2018.292425A method for diagnosis of dysbetalipoproteinemia from the conventional lipid profile.CrossRefPubMed

73.

Pallazola VA, Sathiyakumar V, Park J, Vakil RM, Toth PP, Lazo-Elizondo M, et al. Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Arch Med Sci. 2020;16(5):993–1003. https://doi.org/10.5114/aoms.2019.86972.CrossRefPubMed

74.

Wintjens R, Bozon D, Belabbas K, Mbou F, Girardet J-P, Tounian P, et al. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. J Lipid Res. 2016;57:482–91. https://doi.org/10.1194/jlr.P055699.CrossRefPubMedPubMedCentral

75.

Calandra S, Tarugi P, Bertolini S. Impact of rare variants in autosomal dominant hypercholesterolemia causing genes. Curr Opin Lipidol. 2017;28:267–72. https://doi.org/10.1097/MOL.0000000000000414.CrossRefPubMed

76.

Leren TP, Strøm TB, Berge KE. Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene. Mol Genet Metab Rep. 2016;9:67–70. https://doi.org/10.1016/j.ymgmr.2016.10.007.CrossRefPubMedPubMedCentral

77.

Kato T, Ushiogi Y, Yokoyama H, Hara S, Matsunaga A, Muso E, et al. A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes. CEN Case Rep. 2019;8:106–11. https://doi.org/10.1007/s13730-019-00380-w.CrossRefPubMedPubMedCentral

78.

Wu H, Yang Y, Hu Z. The novel apolipoprotein E mutation apoE Chengdu (c.518T C, p.L173P) in a Chinese patient with lipoprotein glomerulopathy. J Atheroscler Thromb. 2018;25:733–40. https://doi.org/10.5551/jat.41996.CrossRefPubMedPubMedCentral

79.

Sasaki M, Yasuno T, Ito K, Matsunaga A, Hisano S, Abe Y, et al. Focal segmental glomerulosclerosis with heterozygous apolipoprotein E5 (Glu3Lys). CEN Case Rep. 2018;7:225–8. https://doi.org/10.1007/s13730-018-0331-4.CrossRefPubMedPubMedCentral

80.

Tavori H, Fan D, Giunzioni I, Zhu L, Linton MF, Fogo AB, et al. Macrophage-derived apoE Sendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. J Lipid Res. 2014;55:2073–81. https://doi.org/10.1194/jlr.M049874.CrossRefPubMedPubMedCentral

81.•

Iacono D, Feltis GC. Impact of apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan. Aging. 2019;11(2):787–816. https://doi.org/10.18632/aging.101757ApoE in the context of antagonistic pleiotropy.CrossRefPubMedPubMedCentral

82.

Gasparin CC, Leite N, Tureck LV, Souza RLR, Milano-Gai GE, Silva LR, et al. Effects of polymorphisms in APOB, APOE, HSD11β1, PLIN4, and ADIPOQ genes on lipid profile and anthropometric variables related to obesity in children and adolescents. Genet Mol Biol. 2018;41(4):735–41. https://doi.org/10.1590/1678-4685-GMB-2017-0195.CrossRefPubMedPubMedCentral

83.

Karjalainen J-P, Mononen N, Hutri-Kähönen N, Lehtimäki M, Hilvo M, Kauhanen M, et al. New evidence from plasma ceramides links apoE polymorphism to greater risk of coronary artery disease in Finnish adults. J Lipid Res. 2019;60:1622–9. https://doi.org/10.1194/jlr.m092809.CrossRefPubMedPubMedCentral

84.

Xu M, Zhao J, Zhang Y, Ma X, Dai Q, Zhi H, et al. Apolipoprotein E gene variants and risk of coronary heart disease: a meta-analysis. Biomed Res Int. 2016;3912175:1–12. https://doi.org/10.1155/2016/3912175.CrossRef

85.••

Wolters FJ, Yang Q, Biggs ML, Jakobsdottir J, Li S, Evans DS, et al. The impact of APOE genotype on survival: results of 38,537 participants from six population-based cohorts (E2-CHARGE). PLoS One. 2019;(7):e0219668. https://doi.org/10.1371/journal.pone.0219668Numerous findings about apoE from analysis of a very large database.

86.

Zhang Y, Tang H-Q, Peng W-J, Zhang B-B, Liu M. Meta-analysis for the association of apolipoprotein E ε2/ε3/ε4 polymorphism with coronary heart disease. Chin Med J. 2015;128(10):1391–8.CrossRefPubMedPubMedCentral

87.•

Bielak LF, Peyser PA. Genetics of subclinical coronary atherosclerosis. Curr Genet Med Rep. 2018;6(3):116–23. https://doi.org/10.1007/s40142-018-0145-xThe impact of genetic variants in subclinical atherosclerosis.CrossRefPubMedPubMedCentral

88.

Doliner B, Dong C, Blanton SH, Gardener H, Elkind MSV, Sacco RL, et al. Apolipoprotein E gene polymorphism and subclinical carotid atherosclerosis: the Northern Manhattan Study. Stroke Cerebrovasc Dis. 2018;27(3):645–52. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.053.CrossRef

89.

Luo J-Q, Ren H, Banh HL, Liu M-Z, Ping Xu P, Fang P-F, et al. The associations between apolipoprotein E gene Epsilon2/Epsilon3/Epsilon4 polymorphisms and the risk of coronary artery disease in patients with type 2 diabetes mellitus. Front Physiol. 2017;8:1031. https://doi.org/10.3389/fphys.2017.01031.CrossRefPubMedPubMedCentral

90.

Karschnia P, Nishimura S, Louvi A. Cerebrovascular disorders associated with genetic lesions. Cell Mol Life Sci. 2019;76(2):283–300. https://doi.org/10.1007/s00018-018-2934-5.CrossRefPubMed

91.

Math N, Han TS, Lubomirova I, Hill R, Bentley P, Sharma P. Influences of genetic variants on stroke recovery: a meta-analysis of the 31,895 cases. Neurol Sci. 2019;40:2437–45. https://doi.org/10.1007/s10072-019-04024-w.CrossRefPubMedPubMedCentral

92.

Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EbioMedicine. 2020;59:102954. https://doi.org/10.1016/j.ebiom.2020.102954.CrossRefPubMedPubMedCentral

93.

Pechlaner R, Tsimikas S, Yin K, Willeit P, Baig P, Santer P, et al. Very-low-density lipoprotein–associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):790–800. https://doi.org/10.1016/j.jacc.2016.11.065.CrossRef

94.

Sofat R, Cooper JA, Kumari M, Casas JP, Mitchell JP, Acharya J, et al. Circulating apolipoprotein E concentration and cardiovascular disease risk: metanalysis of results from three studies. PLoS Med. 13(10):e1002146. https://doi.org/10.1371/journal.pmed.1002146.

95.••

Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort. Eur Heart J. 2019;40:2813–24. https://doi.org/10.1093/eurheartj/ehz402An informative analysis of apoE in a large study.CrossRefPubMedPubMedCentral

96.

Valanti E-K, Dalakoura-Karagkouni K, Sanoudou D. Current and emerging reconstituted HDL-apoA-I and HDL-apoE approaches to treat atherosclerosis. J Pers Med. 2018;8:34. https://doi.org/10.3390/jpm8040034.CrossRefPubMedCentral

97.

Koopal C, Marais AD, Westerink J, van der Graaf YT, Visseren FLJ. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial. J Lipid Res. 2017;58:2180–7. https://doi.org/10.1194/jlr.M076901.CrossRefPubMedPubMedCentral

98.

Anantharamaiah GM, Garber DW, Goldberg D, Morrel E, Datta G, Palgunachari MN, et al. Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques. J Lipid Res. 2018;59:2075–83. https://doi.org/10.1194/jlr.M085985.CrossRefPubMedPubMedCentral

99.

Gallego-Villar L, Hannibal L, Häberle J, Thöny B, Ben-Omran T, Nasrallah GK, et al. Cysteamine revisited: repair of arginine to cysteine mutations. J Inherit Metab Dis. 2017;40(4):555–67. https://doi.org/10.1007/s10545-017-0060-4.CrossRefPubMedPubMedCentral

100.

Ruhaak LR, van der Laarse A, Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Ann Clin Biochem. 2019;56(3):338–56. https://doi.org/10.1177/0004563219827620.CrossRef

Title: Apolipoprotein E and Atherosclerosis
Author: A. D. Marais
Publication date: 01-07-2021
Publisher: Springer US
Keywords: Dyslipidemia
Arterial Occlusive Disease
Published in: Current Atherosclerosis Reports / Issue 7/2021
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-021-00933-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 7/2021

Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies

HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis

Sustainable Diets for Cardiovascular Disease Prevention and Management

MicroRNAs and Circular RNAs in Lipoprotein Metabolism

COVID and Cardiovascular Disease: What We Know in 2021

mHealth Technology and CVD Risk Reduction

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage